Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Pharming Group ( (PHAR) ) just unveiled an announcement.
Pharming Group reported a robust first quarter in 2025, with total revenues increasing by 42% to $79.1 million compared to the same period in 2024. RUCONEST® revenue surged by 49% to $68.6 million, while Joenja® revenue rose by 9% to $10.5 million, driven by increased patient uptake. The company completed the acquisition of Abliva AB and began the second wave of recruitment for the FALCON clinical trial. Pharming raised its 2025 total revenue guidance and announced the departure of CFO Jeroen Wakkerman. The company also launched Joenja® in England and Wales and is preparing for a U.S. FDA pediatric approval filing.
Spark’s Take on PHAR Stock
According to Spark, TipRanks’ AI Analyst, PHAR is a Neutral.
Pharming Group’s overall stock score reflects a mix of strengths and challenges. The company shows strong revenue growth and a positive strategic outlook, as highlighted in the earnings call. However, financial performance is hindered by profitability issues and negative cash flow. Technical indicators show neutral momentum, while valuation metrics are weak due to unprofitability. Overall, the stock’s outlook is cautiously optimistic, with significant room for improvement in financial health and valuation.
To see Spark’s full report on PHAR stock, click here.
More about Pharming Group
Pharming Group N.V. is a biopharmaceutical company based in the Netherlands, focusing on the development and commercialization of innovative protein replacement therapies and precision medicines. The company is known for its products like RUCONEST®, used for treating acute hereditary angioedema (HAE) attacks, and Joenja® (leniolisib), which targets activated phosphoinositide 3-kinase delta syndrome (APDS). Pharming operates primarily in the U.S. and European markets, with a growing presence in other regions.
Average Trading Volume: 5,816
Technical Sentiment Signal: Hold
Current Market Cap: $600.6M
See more insights into PHAR stock on TipRanks’ Stock Analysis page.